Aftermath of the FDA Vote on Pfizer’s RA JAK Inhibitor, Tofacitinib
After the tofacitinib FDA hearing, the votes are in, false perceptions persist, and patients still need relief.
Some estimate that tofacitinib could be approved by the US FDA within a few months after mixed votes and mostly inaccurate press reports. It’s fitting this discussion takes place as rawarrior.com begins its fourth year of reporting the patient...Continue reading 44 Comments »
Read more